<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029493</url>
  </required_header>
  <id_info>
    <org_study_id>2018SDU-QILU-G116</org_study_id>
    <nct_id>NCT04029493</nct_id>
  </id_info>
  <brief_title>The Situation of Re-infection of Helicobacter Pylori After Successful Eradication</brief_title>
  <official_title>The Situation of Re-infection of Helicobacter Pylori After Successful Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients who accept the quadruple eradication program of the helicobacter pylori and
      success to eradicate helicobacter pylori will be followed-up to observe the situation of
      re-infection of helicobacter pylori.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with helicobacter pylori accepted he quadruple eradication program of the
      helicobacter pylori.They will be followed-up from 1 year to 5 years to observe the situation
      of re-infection of helicobacter pylori.The rate of the re-infection will be described by
      frequency and percentage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of re-infection</measure>
    <time_frame>4 years</time_frame>
    <description>The rate of re-infection will be described by the frequency and percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The influence factors of the rate of re-infection</measure>
    <time_frame>4 years</time_frame>
    <description>The chi-square test will be used to compare the influence factors of the rate of re-infection.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Helicobacter Pylori</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patients in Shandong province, aged between 18 and 70 years old, with previous positive
        H. pylori infection that suceessed to be eradicated by therapies are included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, aged between 18 and 70 years old, with positive H. pylori infection that was
             not eradicated by previous therapies are included. The H. pylori infection is
             confirmed by the positive rapid urease test or 13C-breath test.

        Exclusion Criteria:

          -  Patients with significant underlying disease including liver, cardiac, pulmonary, and
             renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric
             surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,
             NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of
             allergic reactions to any of the medications used in this protocol. Patients
             previously treated with H. pylori eradication regimens or those unwilling to
             participate in the study were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tian Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <phone_ext>053188369277</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tian Ma, MD</last_name>
    <phone>18769781098</phone>
    <phone_ext>053188369277</phone_ext>
    <email>matian1002@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>15588818685</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Tian Ma, MD</last_name>
      <phone>18769781098</phone>
      <phone_ext>15588818685</phone_ext>
      <email>matian1002@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Junnan Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Qiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 21, 2019</last_update_submitted>
  <last_update_submitted_qc>July 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>Re-infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

